Elanco Animal Health (ELAN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
8 Apr, 2026Voting matters and shareholder proposals
Election of two Class I and three Class II director nominees is up for vote at the annual meeting.
Ratification of Ernst & Young LLP as the independent registered public accounting firm for 2026 is proposed.
Advisory vote on executive compensation for named executive officers is included.
Board of directors and corporate governance
Nominees for Class I directors are Kapila Anand and Paul Herendeen.
Nominees for Class II directors are Michael Harrington, Lawrence Kurzius, and Kirk McDonald.
Executive compensation and say-on-pay
Shareholders are asked to provide an advisory vote on the compensation of named executive officers.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Elanco Animal Health
- Proxy details robust growth, governance enhancements, and performance-based executive pay.ELAN
Proxy filing8 Apr 2026 - Innovation-driven growth and operational efficiency position the business for sustained margin expansion.ELAN
BofA Securities Animal Health Summit8 Apr 2026 - Strong innovation, global expansion, and AI-driven efficiencies fuel multi-year growth outlook.ELAN
2026 KeyBanc Capital Markets Healthcare Forum24 Mar 2026 - Innovation and global expansion drive strong revenue and margin growth outlook through 2026.ELAN
Investor presentation20 Mar 2026 - Raised 2026 innovation revenue targets and margin expansion driven by robust product launches.ELAN
Leerink Global Healthcare Conference 202611 Mar 2026 - Innovation and operational strength fuel growth, with 2026 guidance reflecting continued momentum.ELAN
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - Innovation momentum and margin expansion drive strong outlook and long-term growth potential.ELAN
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Q4 2025 saw 12% revenue growth, strong innovation, and raised 2026 guidance with improved leverage.ELAN
Q4 202524 Feb 2026 - Innovation and global reach drive robust growth, margin expansion, and strong 2026 outlook.ELAN
Investor presentation24 Feb 2026